Vaxcyte, Inc. (FRA:5VA)

Germany flag Germany · Delayed Price · Currency is EUR
46.60
+1.20 (2.64%)
At close: Feb 20, 2026
Market Cap7.13B -33.3%
Revenue (ttm)n/a
Net Income-560.13M
EPS-4.13
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume12
Open46.60
Previous Close45.40
Day's Range46.60 - 46.60
52-Week Range24.60 - 79.00
Betan/a
RSI62.94
Earnings DateFeb 24, 2026

About Vaxcyte

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused b... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2013
Employees 414
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 5VA
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements